JP2011526926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526926A5 JP2011526926A5 JP2011516860A JP2011516860A JP2011526926A5 JP 2011526926 A5 JP2011526926 A5 JP 2011526926A5 JP 2011516860 A JP2011516860 A JP 2011516860A JP 2011516860 A JP2011516860 A JP 2011516860A JP 2011526926 A5 JP2011526926 A5 JP 2011526926A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- amide
- carboxylic acid
- phenylamino
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 241000124008 Mammalia Species 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- LQRZNLGKCYARCP-UHFFFAOYSA-N 4-(2-fluoro-4-iodoanilino)-n-(1-hydroxy-2-methylpropan-2-yl)oxy-1h-pyrazolo[3,4-b]pyridine-5-carboxamide Chemical compound OCC(C)(C)ONC(=O)C1=CN=C2NN=CC2=C1NC1=CC=C(I)C=C1F LQRZNLGKCYARCP-UHFFFAOYSA-N 0.000 claims 1
- GQTQXWHZDPDURC-UHFFFAOYSA-N 4-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1,2-benzothiazole-5-carboxamide Chemical compound OCCONC(=O)C1=CC=C2SN=CC2=C1NC1=CC=C(I)C=C1F GQTQXWHZDPDURC-UHFFFAOYSA-N 0.000 claims 1
- YMRXJLXWVAGVBT-UHFFFAOYSA-N 4-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1h-indazole-5-carboxamide Chemical compound OCCONC(=O)C1=CC=C2NN=CC2=C1NC1=CC=C(I)C=C1F YMRXJLXWVAGVBT-UHFFFAOYSA-N 0.000 claims 1
- JKZGFJXSSQZDOU-UHFFFAOYSA-N 4-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1h-pyrazolo[3,4-b]pyridine-5-carboxamide Chemical compound OCCONC(=O)C1=CN=C2NN=CC2=C1NC1=CC=C(I)C=C1F JKZGFJXSSQZDOU-UHFFFAOYSA-N 0.000 claims 1
- IJOPYGAXIHQICU-UHFFFAOYSA-N 4-(2-fluoro-4-iodoanilino)-n-(oxan-4-yloxy)-1h-indazole-5-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOC2CCOCC2)C=CC2=C1C=NN2 IJOPYGAXIHQICU-UHFFFAOYSA-N 0.000 claims 1
- HQBQYHYNUJJVDY-VIFPVBQESA-N 4-(2-fluoro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]-1,2-benzothiazole-5-carboxamide Chemical compound C[C@H](O)CONC(=O)C1=CC=C2SN=CC2=C1NC1=CC=C(I)C=C1F HQBQYHYNUJJVDY-VIFPVBQESA-N 0.000 claims 1
- FXQYDGOQAWPLHY-QMMMGPOBSA-N 4-(2-fluoro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]-1h-pyrazolo[3,4-b]pyridine-5-carboxamide Chemical compound C[C@H](O)CONC(=O)C1=CN=C2NN=CC2=C1NC1=CC=C(I)C=C1F FXQYDGOQAWPLHY-QMMMGPOBSA-N 0.000 claims 1
- PJBCKFFOHMEAQE-UHFFFAOYSA-N 4-(2-fluoro-4-iodoanilino)-n-methoxy-1h-indazole-5-carboxamide Chemical compound CONC(=O)C1=CC=C2NN=CC2=C1NC1=CC=C(I)C=C1F PJBCKFFOHMEAQE-UHFFFAOYSA-N 0.000 claims 1
- AZZLAYRJGBKAJL-UHFFFAOYSA-N 4-(2-fluoro-4-methylsulfanylanilino)-n-(2-hydroxyethoxy)-1h-indazole-5-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOCCO)C=CC2=C1C=NN2 AZZLAYRJGBKAJL-UHFFFAOYSA-N 0.000 claims 1
- IJAVJYYBFRTIAU-UHFFFAOYSA-N 4-(4-bromo-2-fluoroanilino)-n-(2-hydroxyethoxy)-1h-indazole-5-carboxamide Chemical compound OCCONC(=O)C1=CC=C2NN=CC2=C1NC1=CC=C(Br)C=C1F IJAVJYYBFRTIAU-UHFFFAOYSA-N 0.000 claims 1
- ANOLNVJFCNLIDK-VIFPVBQESA-N 4-(4-bromo-2-fluoroanilino)-n-[(2s)-2-hydroxypropoxy]-1h-indazole-5-carboxamide Chemical compound C[C@H](O)CONC(=O)C1=CC=C2NN=CC2=C1NC1=CC=C(Br)C=C1F ANOLNVJFCNLIDK-VIFPVBQESA-N 0.000 claims 1
- RWZBARRAYNKEQD-UHFFFAOYSA-N 7-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1,2-benzothiazole-6-carboxamide Chemical compound OCCONC(=O)C1=CC=C2C=NSC2=C1NC1=CC=C(I)C=C1F RWZBARRAYNKEQD-UHFFFAOYSA-N 0.000 claims 1
- NKWCGFFLRWBOEF-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-n-(2-hydroxyethoxy)-1,2-benzothiazole-6-carboxamide Chemical compound OCCONC(=O)C1=CC=C2C=NSC2=C1NC1=CC=C(Br)C=C1F NKWCGFFLRWBOEF-UHFFFAOYSA-N 0.000 claims 1
- VYIKFFVOVOTEQC-LLVKDONJSA-N 7-(4-bromo-2-fluoroanilino)-n-[(2r)-2,3-dihydroxypropoxy]-1,2-benzothiazole-6-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C2C=NSC2=C1NC1=CC=C(Br)C=C1F VYIKFFVOVOTEQC-LLVKDONJSA-N 0.000 claims 1
- JKTVFQGPPKJXHP-CQSZACIVSA-N 7-(4-cyclopropyl-2-fluoroanilino)-n-[(2r)-2,3-dihydroxypropoxy]-1,2-benzothiazole-6-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C2C=NSC2=C1NC(C(=C1)F)=CC=C1C1CC1 JKTVFQGPPKJXHP-CQSZACIVSA-N 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- OPQRTAHIGADTMO-UHFFFAOYSA-N [4-(2-fluoro-4-iodoanilino)-1h-indazol-5-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)CN1C(=O)C1=CC=C(NN=C2)C2=C1NC1=CC=C(I)C=C1F OPQRTAHIGADTMO-UHFFFAOYSA-N 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- DDHMFHZVMCWHNC-UHFFFAOYSA-N n-(cyclopropylmethoxy)-4-(2-fluoro-4-iodoanilino)-1h-indazole-5-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOCC2CC2)C=CC2=C1C=NN2 DDHMFHZVMCWHNC-UHFFFAOYSA-N 0.000 claims 1
- LILVBVDAEFDXRJ-SNVBAGLBSA-N n-[(2r)-2,3-dihydroxypropoxy]-4-(2-fluoro-4-iodoanilino)-1,2-benzothiazole-5-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C2SN=CC2=C1NC1=CC=C(I)C=C1F LILVBVDAEFDXRJ-SNVBAGLBSA-N 0.000 claims 1
- GSFYVLMDLFXESB-SNVBAGLBSA-N n-[(2r)-2,3-dihydroxypropoxy]-4-(2-fluoro-4-iodoanilino)-1h-indazole-5-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C2NN=CC2=C1NC1=CC=C(I)C=C1F GSFYVLMDLFXESB-SNVBAGLBSA-N 0.000 claims 1
- FOOQXAKAICKOPK-LLVKDONJSA-N n-[(2r)-2,3-dihydroxypropoxy]-7-(2-fluoro-4-iodoanilino)-1,2-benzothiazole-6-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C2C=NSC2=C1NC1=CC=C(I)C=C1F FOOQXAKAICKOPK-LLVKDONJSA-N 0.000 claims 1
- CHULVOSWXYGKAP-LLVKDONJSA-N n-[(2r)-2,3-dihydroxypropoxy]-7-(2-fluoro-4-methylsulfanylanilino)-1,2-benzothiazole-6-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOC[C@H](O)CO)C=CC2=C1SN=C2 CHULVOSWXYGKAP-LLVKDONJSA-N 0.000 claims 1
- BEYHNMFRDWRJGB-UHFFFAOYSA-N n-ethoxy-4-(2-fluoro-4-iodoanilino)-1h-indazole-5-carboxamide Chemical compound CCONC(=O)C1=CC=C2NN=CC2=C1NC1=CC=C(I)C=C1F BEYHNMFRDWRJGB-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7742608P | 2008-07-01 | 2008-07-01 | |
| US61/077,426 | 2008-07-01 | ||
| PCT/US2009/049453 WO2010003025A1 (en) | 2008-07-01 | 2009-07-01 | Bicyclic heterocycles as mek kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011526926A JP2011526926A (ja) | 2011-10-20 |
| JP2011526926A5 true JP2011526926A5 (enExample) | 2012-08-16 |
| JP5544358B2 JP5544358B2 (ja) | 2014-07-09 |
Family
ID=41038842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516860A Expired - Fee Related JP5544358B2 (ja) | 2008-07-01 | 2009-07-01 | 置換二環式ヘテロ環化合物と使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8841462B2 (enExample) |
| EP (1) | EP2310373A1 (enExample) |
| JP (1) | JP5544358B2 (enExample) |
| KR (1) | KR20110029161A (enExample) |
| CN (1) | CN102137847B (enExample) |
| AU (1) | AU2009266956B2 (enExample) |
| BR (1) | BRPI0910175A2 (enExample) |
| CA (1) | CA2727250A1 (enExample) |
| CL (1) | CL2010001641A1 (enExample) |
| IL (1) | IL209931A0 (enExample) |
| MX (1) | MX2010014559A (enExample) |
| PE (1) | PE20110570A1 (enExample) |
| RU (1) | RU2509078C2 (enExample) |
| WO (1) | WO2010003025A1 (enExample) |
| ZA (1) | ZA201008963B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201200651A1 (ru) | 2009-11-04 | 2012-12-28 | Новартис Аг | Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| KR20140034898A (ko) * | 2011-06-09 | 2014-03-20 | 노파르티스 아게 | 헤테로시클릭 술폰아미드 유도체 |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| NO2714752T3 (enExample) | 2014-05-08 | 2018-04-21 | ||
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| CN104119332B (zh) * | 2014-07-08 | 2019-03-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并杂环化合物及其制备方法和用途 |
| CN104860869B (zh) * | 2015-04-03 | 2017-11-03 | 北京大学 | 具有mek激酶抑制功能的化合物及其制备方法与应用 |
| CA2985542C (en) | 2015-05-20 | 2023-10-10 | Amgen Inc. | Triazole agonists of the apj receptor |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| CN109072311A (zh) | 2016-04-15 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| JP7046940B2 (ja) | 2016-10-28 | 2022-04-04 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物 |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| WO2018097944A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
| KR20220110524A (ko) * | 2019-12-04 | 2022-08-08 | 아르커스 바이오사이언시즈 인코포레이티드 | Hif-2알파의 억제제 |
| CN114698376B (zh) | 2020-10-29 | 2022-10-18 | 深圳微芯生物科技股份有限公司 | 作为免疫调节剂的联苯类化合物及其制备方法和应用 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| US12280055B2 (en) | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| CN113336786B (zh) * | 2021-05-31 | 2022-10-18 | 南京工业大学 | 一种非对映选择性的多取代环烷基化合物及其制备方法 |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| WO2026019990A1 (en) | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2017853C3 (de) | 1970-04-14 | 1975-12-11 | Standard Elektrik Lorenz Ag, 7000 Stuttgart | Steuerverfahren zur Sicherung der Informationsverarbeitung und -Übertragung |
| CA920592A (en) * | 1970-05-28 | 1973-02-06 | Denzel Theodor | Amino derivatives of pyrazolo-pyridine carboxylic acids and esters |
| US3736326A (en) * | 1971-03-29 | 1973-05-29 | Squibb & Sons Inc | Isoxazolopyridine carboxylic acids and esters |
| US3780047A (en) * | 1972-07-05 | 1973-12-18 | Squibb & Sons Inc | Derivatives of pyrazolo(3',4'-2,3)pyrido(4,5-e)b-benzo-1,5-diazepines |
| US4012373A (en) * | 1972-09-22 | 1977-03-15 | E. R. Squibb & Sons, Inc. | Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones |
| GB8404586D0 (en) * | 1984-02-22 | 1984-03-28 | Beecham Group Plc | Compounds |
| JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| CA2416685C (en) | 2000-07-19 | 2008-10-07 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| RU2300528C2 (ru) | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек |
| DE60330227D1 (de) | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| GB0316232D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| JP4741491B2 (ja) | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用 |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| ES2299906T3 (es) | 2003-11-25 | 2008-06-01 | Eli Lilly And Company | Moduladores de receptores activados por proliferadores de peroxisomas. |
| WO2005058858A1 (en) | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
| WO2005061476A2 (en) | 2003-12-22 | 2005-07-07 | Basilea Pharmaceutica Ag | Aroylfuranes and aroylthiophenes |
| WO2005063296A2 (en) | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
| AU2006284751A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| DE602006021205D1 (de) | 2005-10-07 | 2011-05-19 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| CA2662285A1 (en) | 2006-08-31 | 2008-03-06 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
-
2009
- 2009-07-01 EP EP09774475A patent/EP2310373A1/en not_active Withdrawn
- 2009-07-01 KR KR1020117002481A patent/KR20110029161A/ko not_active Ceased
- 2009-07-01 AU AU2009266956A patent/AU2009266956B2/en not_active Ceased
- 2009-07-01 PE PE2010001198A patent/PE20110570A1/es not_active Application Discontinuation
- 2009-07-01 CA CA2727250A patent/CA2727250A1/en not_active Abandoned
- 2009-07-01 WO PCT/US2009/049453 patent/WO2010003025A1/en not_active Ceased
- 2009-07-01 US US12/999,003 patent/US8841462B2/en not_active Expired - Fee Related
- 2009-07-01 RU RU2011103454/04A patent/RU2509078C2/ru not_active IP Right Cessation
- 2009-07-01 BR BRPI0910175A patent/BRPI0910175A2/pt not_active IP Right Cessation
- 2009-07-01 MX MX2010014559A patent/MX2010014559A/es active IP Right Grant
- 2009-07-01 CN CN200980133788.0A patent/CN102137847B/zh not_active Expired - Fee Related
- 2009-07-01 JP JP2011516860A patent/JP5544358B2/ja not_active Expired - Fee Related
-
2010
- 2010-12-12 IL IL209931A patent/IL209931A0/en unknown
- 2010-12-13 ZA ZA2010/08963A patent/ZA201008963B/en unknown
- 2010-12-30 CL CL2010001641A patent/CL2010001641A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526926A5 (enExample) | ||
| AU2016219906B2 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| JP2014037426A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2016520618A5 (enExample) | ||
| JP2011507888A5 (enExample) | ||
| JP2006182786A5 (enExample) | ||
| TW201026676A (en) | A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds | |
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| HRP20160036T1 (hr) | Određeni kemijski entiteti, priprave i metode koji sadrže imidazopirimidin | |
| WO2019177975A1 (en) | Antibiotics effective for gram-negative pathogens | |
| CA2983312A1 (en) | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | |
| JP2018501315A5 (enExample) | ||
| JP2012505879A5 (enExample) | ||
| JP2008517913A5 (enExample) | ||
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| JP2012524110A5 (enExample) | ||
| KR20170091154A (ko) | 섬유증의 소분자 억제제 | |
| CN107629022B (zh) | 一种抗菌增效剂及其制法和用途 | |
| SK77096A3 (en) | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adreno-receptor agonists | |
| JP2008519815A5 (enExample) | ||
| JP2010527354A5 (enExample) | ||
| WO2017181974A1 (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
| JP2007507425A5 (enExample) | ||
| RU2003132456A (ru) | Производные арил(или гетероарил)азолилкарбинола для лечения респираторных заболеваний |